Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avenue Therapeutics Inc ATXI

Healthcare Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive... see more

Recent & Breaking News (NDAQ:ATXI)

Abeona Therapeutics Announces Strategy Update and 2021 Financial Results

GlobeNewswire March 31, 2022

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

GlobeNewswire February 15, 2022

Avenue Therapeutics Stock Trading Halted Today

GlobeNewswire February 15, 2022

Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

Accesswire December 15, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

GlobeNewswire December 15, 2021

Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

GlobeNewswire December 12, 2021

Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022

GlobeNewswire November 29, 2021

Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Option

GlobeNewswire November 17, 2021

Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

Accesswire November 12, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

GlobeNewswire November 12, 2021

Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock

GlobeNewswire November 9, 2021

Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs

GlobeNewswire October 25, 2021

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

GlobeNewswire June 14, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

Newsfile April 21, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

PR Newswire April 13, 2021

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Avenue Therapeutics, Inc. (ATXI) Investigation

ACCESSWIRE IA April 13, 2021

Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol

GlobeNewswire April 13, 2021

Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network

GlobeNewswire December 18, 2020

Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis

GlobeNewswire December 18, 2020

Avenue Therapeutics Provides Regulatory Update for IV Tramadol

GlobeNewswire December 17, 2020